Gilead released data from a head-to-head clinical trial showing that its new three-med HIV combo Biktarvy is noninferior to a treatment containing three GlaxoSmithKline drugs. It's the latest wrinkle in a market war that GSK is so intent on winning that it filed a patent lawsuit against Gilead.Original Article
Gilead strikes back at GSK with positive HIV head-to-head trial data for expected blockbuster
